• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Karlin Daniel was granted 150,000 shares, increasing direct ownership by 35% to 575,025 units (SEC Form 4)

    2/5/26 4:54:52 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $DFTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Karlin Daniel

    (Last) (First) (Middle)
    C/O DEFINIUM THERAPEUTICS, INC.
    ONE WORLD TRADE CENTER, SUITE 8500

    (Street)
    NEW YORK NY 10007

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Definium Therapeutics, Inc. [ DFTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/03/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares 02/03/2026 A 150,000(1) A $0.00 575,025 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.
    /s/Mark Sullivan, Attorney-in-Fact for Dan Karlin 02/05/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DFTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFTX

    DatePrice TargetRatingAnalyst
    2/24/2026$25.00Outperform
    Wolfe Research
    1/30/2026$30.00Buy
    Jefferies
    More analyst ratings

    $DFTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Wiley Matthew T. was granted 115,000 shares (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    2/5/26 5:00:10 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Roberts Brandi was granted 150,000 shares (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    2/5/26 4:57:19 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 44% to 407,576 units (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    2/5/26 4:55:45 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Definium Therapeutics Announces New Employee Inducement Grants

    Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of (i) options to purchase an aggregate of 134,540 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the "PSUs") (assuming achievement at target levels of performance) that, if earned, will be settled in Definium common shares upon vesting, with effective grant dates of February 24, 2026, February 27, 2026 and March 9, 2026.

    3/9/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

    Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a

    3/9/26 10:50:00 AM ET
    $ATAI
    $CMPS
    $DFTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

    2/27/26 11:44:00 AM ET
    $ATAI
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $DFTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Definium Therapeutics with a new price target

    Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00

    2/24/26 7:52:18 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies initiated coverage on Definium Therapeutics with a new price target

    Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

    1/30/26 6:43:41 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    SEC Filings

    View All

    SEC Form 10-K filed by Definium Therapeutics Inc.

    10-K - Definium Therapeutics, Inc. (0001813814) (Filer)

    2/26/26 4:16:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Definium Therapeutics, Inc. (0001813814) (Filer)

    2/26/26 4:10:27 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.

    SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)

    2/17/26 9:22:12 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Leadership Updates

    Live Leadership Updates

    View All

    Definium Therapeutics Appoints Roger Adsett to Board of Directors

    Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation

    1/29/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Financials

    Live finance-specific insights

    View All

    Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

    Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder

    2/26/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care